Aiforia Technologies was founded as a spin-off company from the Finnish Institute for Molecular Medicine (FIMM) at the University of Helsinki in 2013 by researchers and pioneers in the field of cloud-based microscopy and pathology and experienced life science entrepreneurs. The Aiforia® Platform brings together deep learning AI and high-performance cloud computing. Aiforia assists with the increased demand for image-based diagnostics by providing efficient and scalable solutions – enabling new discoveries and clinical support with highly accurate and consistent data. Aiforia is technologically driven establishment and keeps the capability of being image agnostic thus extending its solutions to multiple fields.
Arima Genomics develops solutions to drive genomics discovery and human health. Their services include study design consultation, sample preparation, library preparation, bioinformatics analysis, and data interpretation. Their Hi-C technology enables researchers to build chromosome-scale assemblies. Their chromosomal loop arrangement introduces regulatory elements, resulting in altered function.
Asimov is a synthetic biology company that provides an integrated suite of cells, genes, and software to enable advanced genetic design and manufacture of therapies. Their platform includes engineered host cells, a genetic parts library, and cloud-based design software, allowing clients to develop custom cell lines and optimize genetic constructs. Asimov differentiates itself through its comprehensive approach, combining synthetic biology with computational tools, and has achieved significant traction with partnerships across the biotech industry, including over 25 companies from small biotechs to large pharmaceutical firms. The company is positioned at the forefront of the synthetic biology market, leveraging AI and machine learning to enhance genetic engineering capabilities.
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies
Cell Microsystems is an early-growth stage company that develops, manufactures, and markets innovative products for single-cell biology. The company’s proprietary CellRaft™ Technology enables high-efficiency sorting and isolation of single cells under standard culture conditions resulting in unperturbed phenotypes and high viability. Coupled with the company’s automated imaging platform, a user can select a cell in real time and ‘track and trace’ that cell through imaging, collection, and downstream analysis. By sorting during real-time imaging, no cells are wasted enabling single-cell isolation from even small, precious samples. The CellRaft Technology offers scalable solutions making cell separation technology available for every lab.
Deepcell is pioneering new methods in single cell analysis by combining innovations in microfluidics, optics, and AI. The company offers the REM-I platform, which utilizes label-free imaging and deep learning to analyze single cell morphology, providing high-dimensional quantitative readouts. This technology differentiates Deepcell in the market by enabling deep characterization of cells, which is crucial for advancing research in biology and medicine. With a strong foundation from Stanford University, Deepcell is positioned to make significant contributions to biomedical research, particularly in diagnostics and therapeutics, leveraging its advanced AI capabilities and microfluidics technology.
DiaCarta provides precise cancer molecular tests including NRAS, EGFR and KRAS mutation test kits, PCR ready lysis kit, HPV E6/E7 mRNA test kits for cervical and head-neck cancer, cancer biomarker gene expression detection kits and superfast master mix. DiaCarta supplies precise molecular diagnostic cancer assays that enable the most sensitive, reliable, and accurate detection of cancer biomarkers directly from a patient sample, including QClamp gene mutation tests, SuperbDNA gene expression assays, and QZol, the only PCR ready lysate solution . DiaCarta's NRAS, EGFR, and KRAS tests are highly sensitive and able to detect a broad set of mutations and are being used by hospitals and cancer clinical laboratories for the treatment of patients and by biotechnology and pharmaceutical companies for clinical research.
Foundation Medicine is a leader in precision oncology, providing comprehensive genomic profiling tests that identify the genomic alterations driving cancer. Their innovative products, such as Foundation One CDx and Foundation One Liquid CDx, enable personalized treatment strategies by matching patients with targeted therapies and clinical trials. With a strong market position, they have delivered over 1 million reports and contributed to more than 1,000 peer-reviewed publications, making them a trusted partner for healthcare providers and biopharma companies in advancing cancer care.
INDIGO Biosciences supplements the receptor assay kits and services and in vitro toxicology solutions with greater readability, reproducibility, and faster turnaround times of the results. Their solutions, combined with a supportive team and reliable science and platforms, aim to reduce the time, cost, and risk associated with the discovery process.
Locus Biosciences is a precision medicine company focused on developing engineered bacteriophage therapies to combat bacterial infections and address unmet medical needs in immunology, oncology, and CNS disorders. Their innovative LOCUS platform utilizes advanced robotics, AI-driven tools, and synthetic biology to create effective phage cocktails that target specific pathogens while preserving beneficial bacteria in the microbiome. With a commitment to revolutionizing treatment approaches, Locus is positioned to lead in the fight against antibiotic resistance and improve patient outcomes through precision medicine.